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ABSTRACT
Introduction There are no disease- modifying 
treatments for Parkinson’s disease (PD). We undertook 
the irst drug screen in PD patient tissue and 
idntiied ursodeoxycholic acid (UDCA) as a promising 
mitochondrial rescue agent. The aims of this trial are 
to determine safety and tolerability of UDCA in PD at 
30 mg/kg, conirm the target engagement of UDCA, 
apply a novel motion sensor- based approach to quantify 
disease progression objectively, and estimate the mean 
effect size and its variance on the change in motor 
severity.
Methods and analysis This is a phase II, two- centre, 
double- blind, randomised, placebo- controlled trial of 
UDCA at a dose of 30 mg/kg in 30 participants with early 
PD. Treatment duration is 48 weeks, followed by an 
8- week washout phase. Randomisation is 2:1, drug to 
placebo. Assessments are performed at baseline, week 
12, 24, 36, 48 and 56. The primary outcome is safety and 
tolerability. Secondary outcomes will compare the change 
between baseline and week 48 using the following three 
approaches: the Movement Disorders Society Uniied 
Parkinson’s Disease Rating Scale Part 3 in the practically 
deined ‘OFF’ medication state; conirmation of target 
engagement, applying 31Phosphorus MR Spectroscopy to 
assess the levels of ATP and relevant metabolites in the 
brain; and objective quantiication of motor impairment, 
using a validated, motion sensor- based approach. The 
primary outcome will be reported using descriptive 
statistics and comparisons between treatment groups. 
For each secondary outcome, the change from baseline 
will be summarised within treatment groups using 
summary statistics and appropriate statistical tests 
assessing for signiicant differences. All outcomes will 
use an intention- to- treat analysis population.
Ethics and dissemination This trial has been 
approved by the East of England – Cambridgeshire and 
Hertfordshire Research Ethics committee. Results will be 
disseminated in peer- reviewed journals, presentations 
at scientiic meetings and to patients in a lay- summary 
format.
Trial registration number NCT03840005.
INTRODUCTION
Parkinson’s disease (PD) is a progressive 
neurodegenerative disorder comprising 
gait impairment, bradykinesia, rigidity and 
tremor.1 It is the second most common 
neurodegenerative disorder, predicted to 
double in global prevalence between 2005 
and 2030.2 Developing disease- modifying 
therapies is a crucial step in reducing the 
Strengths and limitations of this study
 Ź This is the irst double- blind, randomised, placebo- 
controlled trial of ursodeoxycholic acid (UDCA) in 
Parkinson’s disease (PD).
 Ź This study uses novel secondary outcomes not pre-
viously used in a clinical trial studying PD; name-
ly 31Phosphorus MR spectroscopy (31P- MRS) of 
disease- speciic regions and detailed, complemen-
tary home and clinic- based motor activity and gait 
analysis.
 Ź 31P- MRS will allow the assessment of mitochondrial 
dysfunction directly in the midbrain, including the 
substantia nigra, the most severely affected brain 
area in PD.
 Ź A limitation of the study is the considerable num-
ber of capsules patients will have to take; patients 
will on average be taking an additional nine extra 
capsules of medication each day through the trial, 
signiicantly increasing their ‘pill burden’.
 Ź A further limitation is the small sample size of n=30 
with 20 patients on UDCA and 10 patients on place-
bo, it will not be possible to draw irm conclusions 
about the neuroprotective effect of UDCA in PD but 
will allow for appropriate power and sample size 
calculations for future studies.
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associated morbidity of PD and to delay the develop-
ment of late- stage complications such as dementia, 
postural instability and psychosis.
Mitochondrial dysfunction is a key pathogenic mech-
anism in both sporadic and familial PD and therefore 
a promising target for disease- modifying therapy.3 Our 
group undertook the first drug screen in genetically 
stratified PD patient tissue.4 5 This approach identified 
ursodeoxycholic acid (UDCA) as a particularly prom-
ising mitochondrial rescue compound.5 Other groups 
demonstrated independently the neuroprotective effect 
of UDCA and its taurine conjugate TUDCA in the 1- met
hyl-4- phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse 
model and the rotenone rat model of PD.6 7
The mode of action of UDCA remains to be fully 
elucidated. Current literature would suggest that it 
appears to be Akt mediated. Both ursocholanic acid 
and TUDCA have been demonstrated to induce Akt 
phosphorylation.4 7 Akt activation requires phosphory-
lation at two sites and promotes cell survival through 
several mechanisms, failure of activation is a common 
finding underlying neurodegeneration.4 Reduced Akt 
signalling has been found in in- vitro models of PD and 
in sporadic PD brains postmortem in the substantia 
nigra.8 9
UDCA has been in clinical use for decades primarily 
for primary biliary cholangitis (previously primary 
biliary cirrhosis) with excellent safety and tolerability 
at the standard dose of 15 mg/kg.10 UDCA has also 
been well tolerated at a higher dose of 30 mg/kg over 
2 years in patients with primary sclerosing cholangitis.11 
UDCA is a naturally occurring bile acid but normally 
only forms 1%–3% of total endogenous human bile 
acids. However, in patients on standard therapeutic 
doses of UDCA (13–15 mg/kg/day), UDCA may form 
up to 40% of total bile acids. Intestinal absorption after 
an oral dose is high with a first- pass clearance of about 
50%–60%. Plasma levels reach maximum concentra-
tions after 60 min after ingestion with another peak at 
3 hours.12
A pharmacokinetic study of UDCA in Motor Neurone 
Disease (MND) demonstrated a significant correla-
tion between serum concentration at 1- hour postdose 
and CSF concentration 2 hours postdose, with most of 
the variability in CSF concentrations (78%) explained 
by variability in serum concentrations. Mean CSF 
concentration postdose at 15 mg/kg was 86.69 nmol/L, 
at 30 mg/kg was 114.22 nmol/L and 50 mg/kg was 
191.11 nmol/L.13
The main objectives of this trial (The UP Study) are 
to demonstrate the safety and tolerability of UDCA in 
PD at a dose of 30 mg/kg and to explore the effects 
of UDCA on novel outcome measures such as 31Phos-
phorus MR spectroscopy (31P- MRS) and the objective 
quantification of motor impairment, using a sensor- 
based approach. Additionally, we hope to collect an 
estimate of the effect size and variance of UDCA on the 
change in motor severity of PD over 1 year compared 
with placebo using long- established clinical assessment 
tools.
METHODS AND ANALYSIS
Design
This is a phase II, two- centre, double- blind, randomised, 
placebo- controlled trial of 30 mg/kg of UDCA in early 
PD. Treatment duration with drug or placebo is 48 weeks 
in total, followed by an 8- week washout phase. Thirty 
participants will be included. Randomisation is 2:1 in 
favour of drug to placebo. The choice of 30 mg/kg day 
has been informed by previous pharmacokinetic studies 
in MND, this dose allows effective penetrance of the 
central nervous system but also balances the exposure 
to a potentially higher risk of side effects with increasing 
doses and possible issues with compliance due to the then 
very large number of additional tablets the patients would 
need to take.13
Participants
Patients with early PD, as defined by a clinical diagnosis 
made by a movement disorders specialist according to the 
Queen Square Brain Bank Criteria within 3 years prior 
to recruitment and who demonstrate a clear subjective 
response to dopaminergic medication, confirmed by the 
treating physician, will be recruited from two sites; Shef-
field Teaching Hospitals National Health Service (NHS) 
Trust (STH) and University College London Hospitals 
NHS Foundation Trust (UCLH). Key inclusion and exclu-
sion criteria can be found in box 1.14
Participants are typically recruited through specialist 
movement disorders clinics at both trial sites. The trial 
has also been advertised online by the Parkinson’s 
UK website, the Cure Parkinson’s Trust, the Sheffield 
National Institute for Health- Related Research (NIHR)- 
Biomedical Research Centre website and the NIHR Clin-
ical Research Network websites. Trial advertisements 
direct participants to contact the STH study team to be 
provided with a patient information sheet and a reply 
slip to confirm ongoing interest and to organise a pre- 
screening telephone call to confirm eligibility and suit-
ability for the study.
Study visits either take place at the clinical research 
facility (CRF) of the Royal Hallamshire Hospital, Shef-
field, for STH participants or at the Leonard Wolfson 
Experimental Neurology Centre, Queen Square, London 
for UCLH participants.
Primary outcome
The primary outcome for the UP study is to compare 
the safety and tolerability of UDCA at 30 mg/kg in PD 
compared with placebo as indicated by the following: 
the number of serious adverse events (SAEs), number of 
adverse treatment reactions and the number of patients 
completing the study. The safety and tolerability of 
UDCA in this study will be compared descriptively with 
the reported safety and tolerability of exenatide in the 
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exenatide- PD trial, which followed a broadly similar trial 
design.15
Secondary outcomes
The effect of UDCA versus placebo will be assessed as 
a change from baseline to week 48 for the following 
secondary outcomes:
1. Clinical assessment using the Movement Disorders 
Society Unified Parkinson’s Disease Rating Scale (MDS- 
UPDRS) Part 3 motor examination in the practically- 
defined ‘OFF’ medication state.
2. In vivo measures of high and low energy metabolite 
levels (including adenosine triphosphate (ATP), phos-
phocreatine (PCr) and inorganic phosphate (Pi)) de-
rived from multi- voxel brain 31P- MRS at baseline and 
week 48.
3. Sensor- based, objective quantification of motor impair-
ment using data collected with wearable sensors both 
in supervised (OptoGait and Opals systems, Sheffield 
patients only, Dynaport Movemonitor+, all patients) as 
well as in unsupervised real- life conditions (Dynaport 
Movemonitor+, all patients).
Screening visit
Participants likely to be eligible will be invited for a 
screening visit where all inclusion and exclusion criteria 
will be reviewed. Participants will be offered the oppor-
tunity to discuss the trial and have all questions answered 
after which they will be asked to provide written informed 
consent before proceeding to further assessment. Partici-
pants will have a full demographic, medical and concom-
itant medication history taken and reviewed. A physical 
examination to confirm the diagnosis of PD and exclude 
PD ‘mimic’ conditions will be performed. A Montreal 
Cognitive Assessment (MoCA) and Montgomery- Asberg 
Depression Rating Scale (MADRS) will be performed to 
exclude concurrent dementia or severe active depres-
sion.16 17 Safety bloods (full blood count, urea and 
electrolytes, liver function tests, blood glucose, Haemo-
globin A1C (HbA1C), lipid profile) and an ECG will 
be performed at the screening visit. If the participant 
remains eligible, they will be provided with an activity 
monitor (McRoberts, Dynaport MoveMonitor+) to wear 
for 1 week prior to the baseline visit as described later. 
For those undergoing 31P- MRS, this will be arranged 
within 1 week before or on the day of the baseline visit, 
as described later. The baseline visit will be completed 
within 8 weeks of screening.
Baseline visit, randomisation and blinding
Randomisation to either active compound or placebo will 
be administered using a centralised, web- based system 
hosted by epiGenesys (a wholly owned subsidiary of the 
University of Sheffield) on behalf of the University of 
Sheffield Clinical Trials Research Unit (CTRU).
MDS- UPDRS part 3 Motor Examination is performed 
in the ‘OFF’ state.18 The practically defined ‘OFF’ 
state in this study requires participants to not have 
taken medication for 8 hours in the case of any drug 
containing Levodopa, or at least 36 hours in the case 
of longer- acting agents such as dopamine agonists or 
enzyme inhibitors.
The supervised gait analysis is performed using a combi-
nation of an instrumented photoelectric walkway system 
(Microgate, OptoGait) and inertial sensors (APDM, 
Opal) system as described below.
Participants will then be invited to take their usual 
dopaminergic medication and after a minimum of 60 min 
undergo the following procedures to reassess them in the 
practically defined 'ON' state: MDS- UPDRS Parts 1–4 I 
in the ‘ON’ state, Non- Motor Symptom Questionnaire 
(NMS- QUEST) and The 39- Item Parkinson’s Disease 
Questionnaire (PDQ-39).18–20
Box 1 Key inclusion and exclusion criteria for the UP 
study
Key inclusion criteria
 Ź Diagnosis of Parkinson’s disease (PD) ≤3 years ago based on Queen 
Square Brain Bank criteria.14
 Ź Subjective improvement of motor impairment on dopaminergic 
medication with conirmation by a movement disorders expert.
 Ź Hoehn and Yahr stage ≤2.5 in the practically deined ‘ON’ medica-
tion state.
 Ź Age 18–75 years of any gender.
 Ź Able to comply with study protocol and willing to attend necessary 
study visits.
 Ź Ability to communicate in English.
 Ź Ability to take study drug.
Key exclusion criteria
 Ź Diagnosis or suspicion of other cause of parkinsonism.
 Ź Known abnormality on CT or MRI brain imaging considered likely 
to compromise compliance with 31Phosphorus MR Spectroscopy 
acquisition.
 Ź Known claustrophobia or other reasons why patient could not toler-
ate or be suitable for MRI.
 Ź Current or previous exposure to ursodeoxycholic acid.
 Ź Current or previous diagnosis of liver disease (including biliary 
obstruction), in particular primary biliary cirrhosis judged to be 
signiicant.
 Ź Prior intracerebral surgical intervention for PD (including deep- brain 
stimulation).
 Ź Already actively participating in a trial of a device, drug or surgical 
treatment for PD.
 Ź Participants who lack the capacity to give informed consent.
 Ź History of alcoholism.
 Ź Women of childbearing potential or pregnancy.
 Ź Concurrent severe depression deined by a score >16 on the 
Montgomery- Asberg Depression Rating Scale.
 Ź Concurrent dementia deined by a score lower than 25 on the 
Montreal Cognitive Assessment.
 Ź Any medical or psychiatric condition which in the investigator’s 
opinion compromises the potential participant’s ability to participate.
 Ź Serum transaminases more than two times upper limit of normal.
 Ź Patients on ciclosporin, nitrendipine or dapsone.
 Ź Participants with previous or current diagnosis of inlammatory 
bowel disease.
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Intervention
All study medication is provided as a white powder in a 
hard clear gelatine capsule. Placebo and study drug are 
completely matched with no identifiable differences in 
taste, appearance or smell. All packaging and labelling is 
identical. Each capsule of the active drug contains 250 mg 
of UDCA.
Treatment with UDCA is started at a dose of 250 mg 
(one capsule) per day with an increase by 250 mg every 3 
days until the target dose is reached, which is divided into 
three doses.21 Most patients are expected to reach their 
target dose within 3–4 weeks and be on 9–10 capsules per 
day.
All participants, trial management and medical staff 
will be blinded to treatment. Participants undergo clin-
ical assessments by the same blinded assessor at each 
site who is not involved with safety, AE monitoring or 
dose titration to avoid any assessment bias or accidental 
unblinding.
Assessment procedures
Following randomisation and baseline visit, a total of five 
further visits will be completed at week 12, 24, 36, 48 and 
56. At week 48, treatment is completed and all medica-
tion returned. A final visit at week 56 for final safety moni-
toring and outcome measurement completes the study. 
Week 12 and 36 visits are purely for safety monitoring and 
medication supply.
The MDS- UPDRS part 3 is completed in the practically 
defined ‘ON’ state at week 24 and in the ‘OFF’ state at 
week 48 and 56. The complete MDS- UPDRS (Parts 1–4) is 
completed in the ‘ON’ state at week 48 and 56.
The 31P- MRS is repeated in the 7 days prior to week 
48 for UCLH participants and on the day of the week 48 
visit for STH participants. The week- long unsupervised 
at- home physical activity monitoring (PAM) is repeated 
in the 7 days prior to week 48.
The MoCA, NMS- QUEST, PDQ-39 and MADRS are 
repeated at week 48 and 56.
At each visit, safety bloods (full blood count, urea and 
electrolytes, liver function tests, blood glucose, HbA1C, 
lipid profile) will be obtained. In addition, at each visit a 
20 mL serum sample is taken for long- term storage and 
future research. At the baseline visit, blood is taken for 
genetic analysis, this will be performed using the Neuro-
Chip Assay that assesses for approximately 180 000 genetic 
variants associated with neurological diseases.22
A full schedule of activities can be seen in table 1.
Exploratory outcomes
The exploratory outcomes will consist of the change 
between week 48 and 56 in the following: MDS- UPDRS 
part 3 ‘OFF’ scores, complete MDS- UPDRS (parts 1–4) 
‘ON’ scores, total Levodopa equivalent daily dose, MoCA, 
MADRS, NMS- QUEST and PDQ-39.
The repeat assessments at week 56 (8 weeks after cessa-
tion of the study medication) will help to determine 
whether there is a sustained effect of UDCA on both 
motor and non- motor aspects of PD which would be in 
keeping with the assumption of a neuroprotective effect. 
Conversely, a rapid deterioration of these clinical param-
eters after cessation of the study drug would suggest a 
symptomatic effect of UDCA.
As an additional variable to be used in exploratory anal-
ysis a validated prognostic model calculating the risk of 
progression to an unfavourable outcome (either postural 
instability or dementia at 5 years) will be applied to each 
participant.23 We hope that this variable will account for 
some of the inherent heterogeneity among participants 
for their speed of clinical progression.
Sample size
The primary outcome of interest for this study is the 
safety and tolerability of UDCA which will be assessed by 
comparing the rate of SAEs in the UDCA and placebo 
groups, alongside review of adverse treatment reac-
tions and study completion. As the study is a pilot, it 
is not powered to compare the SAE rate between the 
groups statistically, but any SAEs in either group will be 
presented descriptively, the placebo group providing 
a baseline against which to view any SAEs in the UDCA 
group. Should this study result in no SAEs then it would 
be of interest to determine how likely it is that a larger 
study would find an intolerable rate of SAEs. For this 
purpose, we will consider the rate of SAEs reported in 
the exenatide PD trial to be tolerable and acceptable (ie, 
20%).15 In this study, should no SAEs be found in the 
group receiving UDCA (n=20) then the likelihood that 
the true SAE rate is less than 20% is 0.990778.
The sample size has not been prospectively adjusted 
to account for any lost to follow- up. Instead, as the trial 
is of a relatively short duration we have instead allowed 
for any participants withdrawing from the study or lost to 
follow- up before the completion of 12 weeks of treatment 
to be replaced with a new participant.
The study has not been powered formally for the 
secondary or exploratory outcome measures, therefore, 
interpretation will concentrate on observed trends and 
confidence intervals for estimated differences. The data 
collected for the secondary and exploratory outcomes 
will allow the estimation of the effect size and variance 
in each outcome to facilitate formal power calculations 
for future phase III studies. Of note, there is currently 
no longitudinal clinical trial data using either 31P- MRS 
or our sensor- based approached quantification of motor 
impairment. The collection of such data is critical to allow 
high- quality future trial design using these novel outcome 
measures.
Patient and public involvement
Patient representatives have been involved in the design 
of the study protocol and have contributed to the gener-
ation of participant facing study documentation. Recruit-
ment to the study will be aided by both local PD groups 
and publicised by The Cure Parkinson’s Trust, Parkinson’s 
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UK and Michael J Fox Foundation. Results will be dissem-
inated to all participants on completion of the trial.
OUTCOME MEASURES
Safety monitoring
At each visit, participants are asked to report any AEs 
that have occurred since the previous visit. AEs may also 
be detected by the study team reviewing the patient or 
through notification by the participant’s primary care 
physician. All AEs are assessed by a study doctor for their 
severity, likely relationship to study drug and required 
action by a study doctor not involved in the blinded 
assessment of the patient. All SAEs will be recorded and 
reported to the sponsor regardless of relation to trial treat-
ment within 24 hours. Any suspected unexpected serious 
adverse reactions will be reported to the sponsor imme-
diately to allow facilitation of unblinding as necessary. All 
AEs reported will be reviewed by the trial management 
group, trial steering group and monitored by an indepen-
dent data monitoring committee.
Unblinding requests from other clinicians respon-
sible for a patient’s care will be handled by the principal 
investigator (PI) at each site. The PI at each site may also 
choose to unblind in response to reported AEs as they are 
reported.
In the event that side effects such as diarrhoea do not 
resolve and become persistent or intolerable then the 
patient can have their dose adjusted to their last tolerated 
dose for the remainder of the study.
Table 1 Schedule of activities for the UP study
 
Procedure Screening Baseline
Week 
12
Week 
24
Week 
36
Week 
48
Week 
56
Medical history Consent X       
Review inclusion/
exclusion criteria
X X      
Demographics X       
Medical history and 
physical examination
X       
Height and weight X     X  
Genetics Sample  X      
Medication Randomisation  X      
Medication supply  X X X X   
Concomitant medication 
review
X X X X X X X
Compliance review   X X X X  
Clinical assessment/
outcome measures
MDS- UPDRS Part 3 
‘OFF’
 X    X X
MDS- UPDRS Part 3 ‘ON’    X    
MDS- UPDRS Parts 1–4 
‘ON’
 X    X X
MoCA, MADRS X     X X
PDQ-39  X    X X
NMS- QUEST  X    X  
Sensor- based analysis Dynaport Move Monitor 
+7 days recording
X     X (7 
days 
prior)
 
OptoGait/Opals gait 
assessment ‘OFF’
 X    X  
MRI 31P- MRS  X    X  
Safety monitoring Safety bloods X X X X X X X
ECG X   X    
AE review  X X X X X X
AE, adverse event; MADRS, Montgomery- Asberg Depression Rating Scale; MDS- UPDRS, Movement Disorders Society Uniied Parkinson’s 
Disease Rating Scale; MoCA, Montreal Cognitive Assessment; NMS- QUEST, Non- Motor Symptom Questionnaire; PDQ-39, 39- Item 
Parkinson’s Disease Questionnaire; 31P- MRS, 31Phosphorus MR spectroscopy.
 o
n
 August 25, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-038911 on 5 August 2020. Downloaded from 
6 Payne T, et al. BMJ Open 2020;10:e038911. doi:10.1136/bmjopen-2020-038911
Open access 
All participants will be asked to return unused medi-
cation, this medication will be counted and recorded to 
assess compliance.
Motor measures
The MDS- UPDRS is currently the most used and validated 
clinical tool to quantify the disease state of an individual 
with PD.18 The minimal clinically important difference in 
the MDS- UPDRS part 3 is reported to be an improvement 
of 3.25 points for detecting minimal, but clinically perti-
nent, improvement and a deterioration of 4.63 points for 
observing minimal, but clinically pertinent, worsening.24 
Over a period of 5 years, MDS- UPDRS part 3 scores were 
observed to increase (deteriorate) by 2.4 points per 
year.25 However, despite expected annual deterioration 
being well characterised, rate of decline may still depend 
on disease stage and therefore contemporaneous placebo 
control data remains essential to evaluate potential new 
therapies.
Neuropsychological measures
The MoCA is a globally used and validated measure of 
cognitive impairment and has been used a broad range 
of neurological diseases and study designs.16 The MADRS 
has been validated in PD as a screening tool for major 
depression.17 26
Non-motor and quality of life measures
NMS- QUEST is a clinical screening tool that covers a 
wide range of non- motor symptoms.20 PDQ-39 is a vali-
dated and widely used quality of life questionnaire that 
covers a range of measures such as emotional well- being, 
activities of daily living and mobility in the context of 
PD.19 The total equivalent levodopa dose is calculated 
using calculations and equivalencies generated previ-
ously in a systematic review and allows quantitative 
comparisons between patients on different medication 
regimes.27
31Phosphorous MR spectroscopy
31P- MRS is experienced by the patient in the same manner 
as a standard clinical MRI scan. As the metabolites of 
interest are phosphorus based, it provides the opportu-
nity to investigate key metabolites in bioenergetics such 
as ATP, PCr and Pi which all have clear spectroscopic 
resonances (figure 1). It is, therefore, an ideal approach 
to assess mitochondrial function in vivo. Ratio measures 
such as Pi/ATP and PCr/ATP have been shown to reflect 
the status of different aspects of oxidative phosphoryla-
tion pathways.28
Two- dimensional chemical shift imaging (CSI) with 
image- selected in vivo spectroscopy will be used for spec-
tral spatial localisation,29 30 with a dedicated multinuclear 
MRI system (Ingenia 3.0T, Philips Healthcare, Best, NL) 
and dual- tuned 1H/31P head coil (Rapid Biomedical, Würz-
burg, Germany). Standard clinical T1 and T2- weighted 
imaging will allow the alignment of the two 31P axial CSI 
sequences as shown in figure 2. The two sequences will be 
aligned to obtain spectra from both the putamen (voxels 
for both anterior and posterior putamen bilaterally) and 
the midbrain (one voxel for each left and right). This is a 
clear advantage over alternative techniques that typically 
use surface coils as it allows the localisation of spectra 
to these specific brain regions typically involved in early 
PD. Imaging both anatomical regions is of importance as 
one mechanism of mitochondrial dysfunction in PD may 
be that of retrograde axonal degeneration, therefore, 
spectra from the striatum may show clear mitochondrial 
dysfunction even in early disease independent of findings 
in the midbrain. Previous cross- sectional work using a 
similar 31P- MRS protocol has demonstrated reductions in 
ATP and PCr in PD compared with controls in both the 
putamen and midbrain.31 Additionally, a further study 
demonstrated that Pi/ATP ratios were increased in PD 
compared with controls.32
Details of the acquisition sequences are shown in 
table 2. Spectra will be processed in the time domain 
using jMRUI software V.5.2 (http://www. jmrui. eu) and 
the Advanced Method for Accurate, Robust and Efficient 
Spectral fitting (AMARES) algorithm is used to deter-
mine the relative area under each peak.33–35 Analysis of 
the 31P- MRS data will focus on the change between rando-
misation and week 48 of normalised amplitudes of ATP, 
PCr and Pi, and ratio values such as PCr/ATP and Pi/ATP 
that assess bioenergetic dysfunction. All STH patients 
will undergo 31P- MRS. UCLH patients are also invited to 
attend the STH site for 31P- MRS.
Figure 1 Representative 31P- MRS spectra obtained from 
the midbrain of a healthy volunteer following appropriate 
phasing and 10 Hz Lorentzian apodisation with no 
further editing. From left to right, phosphomonoesters 
(PME), inorganic phosphate (PI), phosphodiesters (PDE), 
phosphocreatine (PCr) and the three spectral resonances of 
adenosine triphosphate (γ-,α-,β-ATP). 31P- MRS, 31phosphorus 
MR spectroscopy.
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Gait analysis and activity monitoring
Physical activity and gait capacity will be assessed at two 
time points, namely prior to/during the baseline visit and 
prior to/during the week 48 visit at the end of the treat-
ment period.
Physical activity will be assessed using home- based ‘real- 
life’ monitoring for seven consecutive days. A lightweight 
PAM containing a triaxial accelerometer, gyroscope, 
digital memory card and a battery (McRoberts, Dynaport 
Movemonitor+Netherlands) has been selected for contin-
uous monitoring in all participants. Participants will wear 
the device for seven consecutive days and complete a 
diary to quantify their physical activity and gait character-
istics within their normal weekly routine in a ‘real- world’ 
setting.
Gait capacity will be assessed during the study visits 
(figure 3) using a combination of wearable inertial sensors 
and an instrumented walkway. In particular, participants 
will complete gait analysis tasks during baseline and week 
48 at the respective centre’s CRFs (STH and UCLH). 
Patients will complete three short gait tasks. First, partic-
ipants will be asked to complete the 3 m timed up and 
go test walk at self- selected speed. It is an assessment of 
functional mobility that incorporates transitional actions 
of standing, turning and sitting.36 37 Then participants 
will complete two continuous gait tasks at self- selected 
preferred, and fast paced walking speeds. Each trial will 
consist of walking back and forth at least six times along 
the 8 m walkway with periods of quiet standing recorded 
at the start and end of each trial. At both sites, partic-
ipants will wear the Dynaport Movemonitor+during 
instrumented gait tasks. At the Sheffield site, an instru-
mented 8 m walkway (OptoGait, Microgate Corporation, 
Bolzano, Italy) and a set of inertial sensors (Opals, APDM, 
Portland, Oregon, USA) will also be implemented. The 
instrumented walkway uses bar- mounted LEDs in a two 
dimensional configuration. The infrared signals trans-
mitted are broken by the movement of the research 
Figure 3 Protocols deployed at the two sites. all 
participants undergo 7- day physical activity monitoring 
in order to estimate physical activity levels and capture 
temporal and gait quality measures in a real- world setting. 
In- clinic instrumented gait tasks are also completed at 
both sites to provide spatiotemporal and gait quality 
measures of gait capacity. At UCL only red sensor location is 
implemented.
Figure 2 The substantia nigra slice is placed to cover 
the midbrain with the highlighted voxels of interest for 
subsequent analyses highlighted in yellow in the sagittal 
(A) and axial planes (B). Placement of 31P- MRS slices. The 
basal ganglia slice is placed over the putamen aligned in 
both the coronal (C) axial planes (D), and voxels of interest 
for subsequent analyses are highlighted in yellow. One 
voxel covers the anterior putamen and another the posterior 
putamen.
Table 2 Detailed parameters of the 31P protocol for acquisition
Sequence 
description Localisation
Decoupling, 
NOE
TR 
(ms)
TE 
(ms) NSA
Acquired 
voxel size 
(mm)
Reconstruction 
matrix
Reconstructed 
voxel size (mm)
Scan 
duration 
(min)
31P- Basal 
Ganglia
31P 2D CSI
ISIS 
localisation
On 4000 0.22 10 40×40×20 12×12 17.5×17.5×20 12:48
31P- 
Substantia 
Nigra
31P 2D CSI
ISIS 
localisation
On 4000 0.22 8 40×40×20 14×14 15×15×20 10:16
CSI, chemical shift imaging; ISIS, image- selected in vivo spectroscopy; NOE, nuclear overhauser efect; NSA, number of signal averages; 
TE, time to echo; TR, time to repetition.
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subject’s feet during walking, and various spatiotemporal 
gait parameters such as step time, stride length, step width 
and stance time are computed. The system has a spatial 
resolution of 1 cm and a temporal resolution of millisec-
onds. The data from the inertial sensors will be used to 
monitor truncal sway during walking and provide a set of 
additional digitally mobility outcomes associated to the 
quality of gait (eg, gait smoothness, variability, symmetry, 
etc).38 39 The sensors will be positioned at both ankles, 
the lower back (L5), upper back (C7) and forehead. Each 
sensor contains an accelerometer, gyroscope and magne-
tometer and records synchronised data wirelessly. Data 
will be analysed with previously published, validated state 
of the art algorithms, implemented in Matlab.38 40 41
STATISTICAL ANALYSIS
These analyses will include all randomised patients (an 
intention- to- treat analysis population). The primary 
outcome of safety and tolerability will be reported using 
descriptive statistics and comparisons between treatment 
groups. Demographic and clinical assessment data will be 
summarised.
For each of the secondary outcomes, the change from 
baseline will be summarised within treatment groups 
using standard summary statistics (number of partici-
pants, mean, SD, median, minimum and maximum) with 
appropriate statistical tests assessing for significant differ-
ences depending on the distribution of the data and any 
relevant covariates.
DATA MANAGEMENT
Data will be kept in accordance with Good Clinical 
Practice, the Data Protection Act 2018 and General 
Data Protection Regulations. Data management will be 
provided by the University of Sheffield CTRU. All data 
will be entered remotely on to a centralised database held 
within the CTRU (Prospect) by a research study member 
at the study site. Access to Prospect is controlled by user-
names and encrypted passwords.
All participants will be assigned a unique participant 
ID number at screening that will link all of the clinical 
information held about them on the study database. It 
will also be used in all correspondence between CTRU 
and participating centres.
ETHICS AND DISSEMINATION
This trial has been approved by the East of England – 
Cambridgeshire and Hertford Shire Research Ethics 
committee (Protocol ID: 18/EE/0280) in November 
2018. The study will be conducted in accordance with 
the local R&D approval and the Declaration of Helsinki. 
All participants provide written informed consent prior 
to any study procedures commencing. The results will be 
published in a peer- reviewed journal and presented at 
regional, national and international scientific meetings as 
appropriate. A plain English summary of the study results 
will be sent to the study participants once data analysis 
has been completed. Results of the study may also be 
presented at meetings of PD support groups or to other 
relevant lay audiences.
DISCUSSION
We propose a novel study design for early, proof of concept 
PD neuroprotection trials, combining assessment for 
safety and tolerability with 31P- MRS- based assessment of 
target engagement of bioenergetics pathways and motion 
sensor- based objective quantification of disease progres-
sion. Our study protocol will be particularly powerful for 
any compound aiming to directly improve mitochondrial 
function in PD. Additionally, our approach of using 31P- 
MRS also holds promise to determine biologically relevant 
target engagement for compounds aiming at genetically 
defined upstream targets such as antisense oligonucle-
otides for LRRK2 or antibody therapy for alpha- synuclein. 
Mitochondrial dysfunction is a well- recognised aspect of 
both LRRK2- and alpha- synuclein- associated PD.42 43
A recent open- label study of UDCA over 6 weeks with 
an escalating dose up to 50 mg/kg in five patients with 
mild to moderate PD found reasonable tolerability 
and also used 31P- MRS to assess target engagement.44 
However, their 31P- MRS imaging data were obtained in 
only three participants and their methodology differed in 
that a surface coil was used and to acquire occipital lobe 
spectra only.
In- depth sensor- based gait analysis has the potential 
to overcome the current limitations of the MDS- UPDRS- 
based clinical assessment.18 Gait analysis provides a 
method of quantifying gait disability and postural insta-
bility and therefore has potential as an objective motor 
endpoint for future studies. There is clear evidence that 
greater axial involvement predicts a poorer outcome in 
PD with regard to both cognitive decline and postural 
instability.23 It is, therefore, likely that the greatest value 
in sensor- based analysis is in assessing a combination of 
spatiotemporal and upper body gait characteristics both 
in the formal clinical setting but also in exploring real- life 
mobility through at- home monitoring.38 45 46
UDCA has previously been trialled in another neurode-
generative disorder, MND at doses of 15, 30 and 50 mg/kg 
in a total of 18 patients. Patients were treated for 4 weeks. 
The main AEs were minor gastrointestinal side effects, 
graded as mild to moderate. Side effect profiles and 
frequency were broadly similar between groups without 
a clear dose correlation.13 This represents grounds to 
hypothesise that the primary outcome of safety and toler-
ability of UDCA at 30 mg/kg in PD will be achievable. We 
expect completion of the study analysis by July 2021.
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